CASE STUDY

Decentralized in Action: How Science 37 Accelerated Enrollment for a Diagnostic Oncology Trial.

A biopharma company was investigating how its diagnostic screening technology—a one-time blood sample—performed against the gold standard cancer screening procedure. The protocol required 25,000 average-risk patients between the ages of 45 and 85 to enroll. The sponsor also looked to include a diverse and representative population in the trial.

Science 37 implemented a Metasite™, enabling a hybrid model with direct-to-patient capabilities, leveraging community-based provider locations. All procedures occurred exactly as they would in a traditional trial, using the same collection methods, processing steps, and a central lab. For the direct-to-patient group, blood draws were performed at home. Screening procedures were performed in a clinical setting by qualified gastroenterologists. This approach enabled decentralization on a massive scale.

- ✓ **Virtual Investigators**
- ✓ **Mobile Phlebotomy**
- ✓ **Unified Technology Platform**

The Results

- 25,000 Medical Records Collected
- 12,000 Participants Enrolled
- 24.2% Minority Representation
- 80+ Community Provider Locations

The Science 37 Metasite enrolled nearly 50% of the entire study with 24.2% minority representation, enabling recruitment and access across 49 states.

This accelerated approach resulted in a more than 3-year reduction of the clinical trial timeline.

Let's Talk

Accelerate your Clinical Research with a Metasite for Oncology.

sales@science37.com / science37.com